Jonathan M. Young
Net Worth

Last updated:

What is Jonathan M. Young net worth?

The estimated net worth of Dr. Jonathan M. Young is at least $20,898,242 as of 10 Dec 2024. He owns shares worth $9,679,693 as insider, has earned $8,113,549 from insider trading and has received compensation worth at least $3,105,000 in Akero Therapeutics, Inc..

What is the salary of Jonathan M. Young?

Dr. Jonathan M. Young salary is $621,000 per year as Co-Founder, Executive Vice President, Chief Operating Officer & Sec. in Akero Therapeutics, Inc..

How old is Jonathan M. Young?

Dr. Jonathan M. Young is 55 years old, born in 1970.

What stocks does Jonathan M. Young currently own?

As insider, Dr. Jonathan M. Young owns shares in one company:

Company Title Shares Price per share Total value
Akero Therapeutics, Inc. (AKRO) Co-Founder, Executive Vice President, Chief Operating Officer & Sec. 203,783 $47.5 $9,679,693

What does Akero Therapeutics, Inc. do?

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO logo
AKRO
Akero Therapeutics, Inc.
$47.5

Jonathan M. Young insider trading

Akero Therapeutics, Inc.

Dr. Jonathan M. Young has made 38 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,503 units of AKRO stock worth $77,067 on 10 Dec 2024.

The largest trade he's ever made was exercising 83,321 units of AKRO stock on 1 Mar 2024. As of 10 Dec 2024 he still owns at least 203,783 units of AKRO stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,503 $30.79 $77,067
Sale
Common Stock 10,000 $32.13 $321,310
Sale
Common Stock 34,943 $31.25 $1,092,109
Sale
Common Stock 15,481 $32.27 $499,525
Sale
Common Stock 292 $32.94 $9,618
Option
Common Stock 40,716 $21.09 $858,700
Option
Stock Option (Right to Buy) 40,716 $21.09 $858,700
Sale
Common Stock 40,000 $30.15 $1,206,080
Option
Common Stock 40,000 $21.09 $843,600
Option
Stock Option (Right to Buy) 40,000 $21.09 $843,600
Sale
Common Stock 10,000 $28.18 $281,770
Sale
Common Stock 568 $26.18 $14,870
Sale
Common Stock 1,290 $27.58 $35,573
Sale
Common Stock 3,710 $26.42 $98,014
Sale
Common Stock 3,031 $26.44 $80,140
Sale
Common Stock 1,969 $27.23 $53,616
Sale
Common Stock 5,000 $19.29 $96,440
Sale
Common Stock 5,000 $20.15 $100,750
Sale
Common Stock 4,600 $24.33 $111,904
Sale
Common Stoek 400 $25.03 $10,010
Sale
Common Stock 651 $28.33 $18,443
Option
Stock Option (Right to Buy) 83,321 $0.62 $51,242
Option
Common Stock 83,321 $0.62 $51,242
Sale
Common Stock 5,414 $24 $129,936
Option
Common Stock 5,414 $6.36 $34,433
Option
Stock Option (Right to Buy) 5,414 $6.36 $34,433
Sale
Common Stock 543 $20.76 $11,273
Sale
Common Stock 30,000 $14.68 $440,250
Option
Stock Option (Right to Buy) 490 $21.1 $10,339
Sale
Common Stock 490 $51.1 $25,039
Option
Common Stock 490 $21.1 $10,339
Sale
Common Stock 538 $55.16 $29,676
Option
Common Stock 8,777 $0.62 $5,398
Option
Employee Stock Option (Right to Buy) 8,777 $0.62 $5,398
Sale
Common Stock 8,777 $54.64 $479,558
Option
Employee Stock Option (Right to Buy) 722 $0.62 $444
Option
Common Stock 722 $0.62 $444
Option
Common Stock 11,778 $6.36 $74,908
Option
Employee Stock Option (Right to Buy) 11,778 $6.36 $74,908
Sale
Common Stock 12,500 $49.57 $619,613
Option
Common Stock 12,500 $6.36 $79,500
Option
Stock Option (Right to Buy) 12,500 $6.36 $79,500
Sale
Common Stock 12,500 $44.72 $558,950
Option
Employee Stock Option (Right to Buy) 26,296 $0.62 $16,172
Option
Employee Stock Option (Right to Buy) 1,448 $0.62 $891
Option
Common Stock 27,744 $0.62 $17,063
Sale
Common Stock 6,220 $24.33 $151,333
Sale
Common Stock 18,780 $24.27 $455,791
Sale
Common Stock 12,500 $24.04 $300,500
Option
Employee Stock Option (Right to Buy) 9,000 N/A N/A
Option
Common Stock 9,000 N/A N/A
Sale
Common Stock 3,055 N/A N/A
Sale
Common Stock 3,055 N/A N/A
Sale
Common Stock 3,055 $28.75 $87,828
Sale
Common Stock 3,055 $30.8 $94,094
Sale
Common Stock 3,055 $30.8 $94,094
Sale
Common Stock 3,055 $29.56 $90,291
Sale
Common Stock 3,055 N/A N/A
Sale
Common Stock 10,000 $28.12 $281,200
Option
Employee Stock Option (Right to Buy) 7,500 $0.62 $4,613
Option
Common Stock 7,500 $0.62 $4,613
Sale
Common Stock 3,060 $25.64 $78,443
Sale
Common Stock 3,060 $25.64 $78,443
Option
Stock Option (Right to Buy) 11,117 $0.62 $6,837
Option
Stock Option (Right to Buy) 11,117 $0.62 $6,837
Option
Common Stock 11,117 $0.62 $6,837
Option
Stock Option (Right to Buy) 38,907 $0.62 $23,928
Option
Common Stock 38,907 $0.62 $23,928

Akero Therapeutics key executives

Akero Therapeutics, Inc. executives and other stock owners filed with the SEC: